Folotyn (Pralatrexate)
pralatrexate 20 mg/mL injection, 1 mL vial · INJECTION · PBS code 11293J
AUTHORITY_REQUIREDWhat it costs
AU$1035.5 PBS-determined price per pack
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2018-04-01.
- • Repeats: 5.
- • PBS program: IP.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Relapsed or chemotherapy refractory Peripheral T-cell Lymphoma
Initial treatment
The condition must be relapsed or chemotherapy refractory; AND
Patient must have undergone appropriate prior front-line curative intent chemotherapy; AND
The treatment must be the sole PBS-subsidised systemic anti-cancer therapy for this PBS indication.
Sponsor: Mundipharma Pty Limited ABN 87 081 322 509
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.